- Home
- HUIZ vs HIND Comparison
HUIZ vs HIND Comparison
Compare HUIZ & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HUIZ | HIND |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | 2 |
| Industry | Specialty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 15.2M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | HUIZ | HIND |
|---|---|---|
| Price | $1.69 | $2.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.30 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.8M | 8.1K |
| Earning Date | 06-05-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | $8.58 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $7.81 | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $1.04 | $1.75 |
| 52 Week High | $4.16 | $12.00 |
Technical Indicators
Market Signals| Indicator | HUIZ | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 58.96 |
| Support Level | $1.33 | $1.99 |
| Resistance Level | $1.87 | $2.35 |
| Average True Range (ATR) | 0.39 | 0.10 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 25.00 | 79.88 |
Price Performance
Historical ComparisonAbout HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.